Table 2.

Treatment parameters and intermediate outcomes for patients who were treated by INHD and matched control subjects who were on CHD as of January 1, 2007 (includes mean of last recorded values obtained from the previous month)

ParameterIn-Center Long-Term Hemodialysis
INHDCHD
Treatment information
    time (min; mean ± SD)470 ± 29222 ± 28
    BFR (ml/min; mean ± SD)306 ± 58414 ± 57
    DFR (ml/min; mean ± SD)496 ± 118682 ± 129
    dialyzer surface area (%)
        1.5 m272.844.0
        1.8 m224.947.9
        2.0 m22.17.5
    other dialyzers0.20.6
SF-36 quality-of-life scores (mean ± SD)a
    PCS37.5 ± 11.733.1 ± 10.6
    MCS49.0 ± 10.6b47.9 ± 11.2
Laboratory variables (mean ± SD)
    eKt/V2.21 ± 0.561.46 ± 0.32
    hemoglobin (g/dl)12.16 ± 1.43b12.11 ± 1.40
    albumin (g/dl)3.95 ± 0.363.81 ± 0.42
    phosphorus (mg/dl)5.31 ± 1.54c5.50 ± 1.64
    TSat (%)25.4 ± 9.927.2 ± 11.2
Interdialytic weight gain (kg; mean ± SD)4.0 ± 1.52.8 ± 1.2
Interdialytic weight gain (% of weight; mean ± SD)4.4 ± 1.63.7 ± 1.4
UF volume (L; mean ± SD)4.0 ± 1.42.5 ± 1.1
UF rate (ml/h per kg; mean ± SD)6.0 ± 2.08.8 ± 2.9
Predialysis SBP (mmHg; mean ± SD)147.7 ± 21.1d149.9 ± 21.5
Postdialysis SBP (mmHg; mean ± SD)130.4 ± 19.4135.3 ± 18.9
  • a Only one in five patients with SF-36 scores in both groups (20.5% for INHD and 23.4% for CHD).

  • b P = 0.3,

  • c P = 0.003,

  • d P = 0.009 versus CHD (all others at P < 0.0001).